Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $317.3 million.

  • Akebia Therapeutics' Total Non-Current Liabilities rose 2551.29% to $317.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $317.3 million, marking a year-over-year increase of 2551.29%. This contributed to the annual value of $264.7 million for FY2024, which is 47.57% up from last year.
  • Per Akebia Therapeutics' latest filing, its Total Non-Current Liabilities stood at $317.3 million for Q3 2025, which was up 2551.29% from $302.2 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Total Non-Current Liabilities high stood at $436.1 million for Q1 2022, and its period low was $246.0 million during Q1 2024.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $302.2 million (2025), whereas its average is $314.5 million.
  • In the last 5 years, Akebia Therapeutics' Total Non-Current Liabilities crashed by 3503.97% in 2023 and then skyrocketed by 2551.29% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Total Non-Current Liabilities stood at $371.1 million in 2021, then dropped by 9.71% to $335.1 million in 2022, then dropped by 21.4% to $263.4 million in 2023, then grew by 0.48% to $264.7 million in 2024, then grew by 19.9% to $317.3 million in 2025.
  • Its last three reported values are $317.3 million in Q3 2025, $302.2 million for Q2 2025, and $278.4 million during Q1 2025.